Axillary Staging Successfully Omitted in Most Early Breast Cancer Cases

A prospective study applied criteria from the SOUND, INSEMA, and BOOG 13-08 trials to omit sentinel lymph node biopsy (SLNB) in postmenopausal women with cT1-2N0, grade 1/2, HR+/HER2- breast cancer and a normal axillary ultrasound undergoing breast-conserving surgery. Among 437 patients, SLNB was ultimately avoided in 97%, with 8% found to have high-risk features on final pathology prompting multidisciplinary discussion; at a median follow-up of 7.7 months, no axillary recurrences were reported.

Most relevant for: Postmenopausal women aged 50-70 with early-stage, hormone receptor-positive, HER2-negative breast cancer undergoing breast-conserving surgery with a clinically negative axilla.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.